Next Step For MRD Testing In MM
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses Next Step For MRD Testing In MM at Lymphoma & Myeloma on ...
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD Testing: Primary Endpoint For Drug Development
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses MRD Testing: Primary Endpoint For Drug Development at Lym...
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD Detection In MM
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses MRD Detection In MM at Lymphoma & Myeloma on October ...
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
How Can A Private Practice Doctor Use MRD
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses How Can A Private Practice Doctor Use MRD at Lymphoma & M...
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Drug Repurposing For Myeloma Patients
Samir Parekh, M.D. Associate Professor of medicine, hematology, medical oncology, and oncological sciences at the Icahn School of Medicine at Mount Sinai Discusses Drug Repurposing For Myeloma Patient...
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Mcbane-ELIQUIS(Apixaban) In Non Cancer Setting
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ELIQUIS(Apixaban) In Non Cancer Setting At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: ASHReport
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
ADAM-VTE Trial: Upper Extremity & amp; Splenic DVT
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial: Upper Extremity & Splenic DVT At The 60th ASH Annual Meeting on Dec 1, 20...
Author: ASHReport
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
ADAM-VTE Trial Overall Event Rates
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial Overall Event Rates At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: ASHReport
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
AstraZeneca The Leader In Hematology
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses AstraZeneca The Leader In Hematology At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: ASHReport
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Acalabrutinib Monotherapy In CLL
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Monotherapy In CLL At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: ASHReport
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Acalabrutinib Key Clinical Data
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Key Clinical Data At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: ASHReport
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Where Does The Lyra Study Regiment Fit
Habte Yimer, M.D. Chairman, Hematology/Oncology Department, CHRISTUS Trinity Mother Frances Hospital, Medical Oncology Specialist in Tyler, TX Discusses Where Does The Lyra Study Regiment Fit At The 6...
Author: ASHReport
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Lyra: Front Line, First Relapse Study For MM
Habte Yimer, M.D. Chairman, Hematology/Oncology Department, CHRISTUS Trinity Mother Frances Hospital, Medical Oncology Specialist in Tyler, TX Discusses Lyra: Front Line, First Relapse Study For MM At...
Author: ASHReport
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
ADAM-VTE Trial Summary
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial Summary At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: ASHReport
Added: 12/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 19, 2018 Category: Cancer & Oncology Source Type: podcasts
The Future Of Daratumumab
Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses The Future Of Daratumumab At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: ASHReport
Added: 12/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 19, 2018 Category: Cancer & Oncology Source Type: podcasts
